Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ È£¸£¸ó ¼ö¿ëü, PCNA, AgNOR ¹× Á¶Á÷ÇÐÀû ¼Ò°ß°£ÀÇ ºñ±³¿¬±¸ A Comparative Study of PCNA Immunostaining, AgNOR Scores Hormone Receptors and Histology in Human Breast Cancer

´ëÇѺ´¸®ÇÐȸÁö 1993³â 27±Ç 6È£ p.605 ~ 617
±èÇüÅÂ, ¼Õ½Â¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇüÅ (  ) 
°è¸í´ëÇб³

¼Õ½Â¿ø (  ) 
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract

¿ä ¾à
1990³âºÎÅÍ 1991³â±îÁö °è¸í´ëÇб³ µ¿»êº´¿ø º´¸®°ú¿¡¼­ °Ë»öµÈ ¿ø¹ß¼º À¯¹æ¾Ï 50¿¹¸¦ ´ë
»óÀ¸·Î ÇÏ¿© ÀÓ»ó°æ°úÀÇ ÃßÀûÁ¶»ç, À°¾ÈÀû ¼Ò°ß, Çö¹Ì°æÀû ¼Ò°ß, ER°ú PRÀÇ À¯¹« ±×¸®°í Á¾
¾ç Áõ½Ä·Â ÃøÁ¤À» À§ÇÏ¿© PCNAÀÇ ¸é¿ª¹ÝÀÀÀ» º¸±âÀ§ÇÑ avidin/biotin immunoperoxidase¿°
»öÀ» ½ÃÇàÇÏ°í ¶Ç Àº¿°»öÀ» ÇÏ¿© AgNOR¼ö¸¦ °ËÁõÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù.
1) ER-/PR-À϶§¿¡ mAgNORsÄ¡ÀÇ Áõ°¡°¡ °æ°è¼± À¯ÀǼºÀÌ ÀÖ¾ú´Ù(f=0.08).
2) ER-/PR-À϶§¿¡ PCNAÀÇ Áõ°¡´Â À¯ÀǼºÀÌ °ÅÀÇ ¾ø¾úÀ¸³ª(f=0.25) °æÇâÀº ÀÖ¾ú´Ù
(f=0.13).
3) ER/PR»óÅÂ¿Í Á¶Á÷ÇÐÀû µî±Þ°úÀÇ °ü°è´Â À¯ÀǼºÀÌ ÀÖ¾ú´Ù(f=0.005, f=0.015).
4) ħÀ±¼º µµ°ü¾Ï¿¡¼­ mAgNORsÄ¡¿Í Á¶Á÷ÇÐÀû µî±Þ°ú´Â µî±Þ 1°ú µî±Þ 3À» ºñ±³ÇÏ¿© µî
±Þ 3¿¡¼­ À¯ÀǼº ÀÖ°Ô »ó½ÂÇÏ¿´´Ù(P<0.05). ¶Ç º´±â¿ÍÀÇ °ü°è´Â º´±â ¥±A¿¡¼­ ºÎÅÍ º´±â ¥²
±îÁö »ó½ÂÇÏ¿´´Âµ¥ °æ°è¼± À¯ÀǼºÀÌ ÀÖ¾ú´Ù(f=0.07)
5) PCNAÄ¡´Â Á¶Á÷ÇÐÀû µî±Þ ¹× º´±â¿ÍÀÇ °ü°è´Â À¯ÀǼºÀÌ ¾ø¾ú´Ù.
6) ER-/PR-ÀÌ°í Á¶Á÷ÇÐÀû µî±Þ 3ÀÌ°í °í PCNAµî±ÞÀ̰ųª ¶Ç´Â mAgNORÄ¡°¡ ³ôÀ¸¸é
(>2.69) Á¾¾çÁõ½ÄÀ²ÀÌ ³ô¾Æ ¾î´À º´±â¿¡ »ó°ü¾øÀÌ º´ÀÇ °æ°ú°¡ ½Å¼ÓÈ÷ ÁøÇàµÇ¾î ¿¹ÈÄ°¡ ÈÎ
½Å ³ª»Ú´Ù.
ÀÌ»óÀÇ °á°ú·Î À¯¹æ¾ÏÀÇ ¿¹Èĸ¦ ÆÇÁ¤Çϴµ¥´Â Á¶Á÷ÇÐÀû µî±Þ º´±â ±×¸®°í ER°ú PRÀÇ °Ë
»ç¿Ü¿¡ Á¾¾çÀÇ Áõ½Ä·ÂÀ» ÃøÁ¤ÇÒ ¼ö ÀÖ´Â AgNORs¿Í PCNA°Ë»çµµ µ¿½Ã¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ ¿¹
Èĸ¦ ÆÇÁ¤Çϴµ¥ º¸´Ù À¯¸®Çϸç ƯÈ÷ À¯º°³ª°Ô Áõ½ÄÀ²ÀÌ ³ô°í Àü°ÝÀûÀ¸·Î º´ÀÌ ÁøÇàÇÏ´Â ÀÌ
Áú¼º Á¾¾çÀ» °¡·Á³»¾î ±× ³ª»Û ¿¹ÈÄÀÇ ¿¹°ß ¹× Ä¡·á´ëÃ¥ °áÁ¤¿¡ ¸Å¿ì Áß¿äÇÏ°Ô ±â¿©ÇÒ ¼ö
ÀÖ´Ù°í »ý°¢µÈ´Ù.
#ÃÊ·Ï#
This study was performed on 50 cases of primary breast cancer removed surgically
during the period 1990¡­1991 and compared the results of four morphologic methods
developed for the detection of estrogen receptors, progesterone receptors, monoclonal
antibody PCNA immunoreactivity, and the mean number of argyrophilic nucleolar
organizer regions(mAgNORs) to ascertain the prognostic significance and also to detect
highly malignant heterogenous cancer. To determine the validity of these measurements,
a variance analysis was done with Kruskal-W allis 1-way AN OVA. The results
showed that the significant correlation between histologic grade and ER/PR status(f=
0.005/f=0.015), the borderline significant correlation between mAgNORs and ER/PR
status(f=0.08), and between AgNORs and stage(f=0.07), PCNA has no correlation with
ER/PR status(f=0.25), clinical stage and histologic grade.
In follow up, four cases of invasive ductal carcinoma with ER/PR, developed early and
rapid metastasis within 2 years, three of them were classified as histologic grade 3 and
another case was grade 2, whereas two of them were classified as stage ¥²(+) and the
rest were in stage ¥±B (+) and stage ¥±A(-). The mAgNOR count of these four cases
were ranged from 3.32 to 4.29 which were in the aneuploid category most likely. One of
them had rather stormy rapid course with multiple organ metastases resulting death
within one year.
These results indicated that ductal carcinoma(>2§¯ size) with ER-/PR- and high
mAgNOR level or high PCNA grade, and high histologic grade had a highly malignant
course, marked by rapidly developing metastases. Thus we concluded that the status of
ER/PR alone in tumor tissue is an important information for selecting hormone
treatment but, for the ultimate prognosis, is a weak indicator. Therefore for early
detection of such heterogenous tumor, besides ER/PR, AgNORs or PCNA, histologic
grade and tumor size are very useful as biological indicators of prognosis.
The status ER/PR in combination with these indicators are more accurate and provide
better basis on which to base a decision for early implementation of chemotherapy from
which to give probably benefit by inhibition of rapid progress. (Korean J Pathol 1993;
27: 605¡­617)

Å°¿öµå

Breast Cancer; ER; PR; AgNOR; PCNA;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS